Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a bona fide gift of 12,539 shares of common stock on August 31, 2026. The transaction was a disposition by gift, not a sale for value, and Owen now holds 66,100 shares of Adaptive Biotechnologies common stock directly.
Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a sale of company stock. On 2026-08-26, Owen sold 9,615 shares of Common Stock in a sale in open market or private transaction at $26.00 per share, and reported owning 78,639 shares of Common Stock directly after the transaction.
Adaptive Biotechnologies Corp (symbol ADPT) received a Rule 144 notice from director Katherine E. Owen covering a planned sale of up to 9,615 shares of common stock. The shares are associated with restricted stock awards granted in 2022, 2023, and 2025 and are to be sold through Morgan Stanley Smith Barney LLC. The filing reports an aggregate market value of approximately $249,990 for the shares, with an approximate sale date of August 26, 2026 on NASDAQ.
Adaptive Biotechnologies Corp (ADPT) reports that former officer Harlan Robins plans to sell up to 402160 shares of common stock through Goldman Sachs & Co. LLC under Rule 144, with an aggregate market value of 10230950.4. These shares were acquired on 03/04/2022 as compensation via stock options and are designated for a cashless exercise / same-day sale. The notice also lists multiple prior open-market sales of Adaptive Biotechnologies common stock by Robins during the past three months.
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg reported an option exercise and related share sales. On 2026-08-18, he exercised a stock option for 15,000 shares of common stock at an exercise price of $6.32 per share, fully using an option that would have expired on October 18, 2026. He then sold 30,664 shares of common stock in two transactions at weighted average prices of $24.39 and $24.41 per share, with actual sale prices ranging from $24.38–$24.44 as disclosed in the footnotes.
Adaptive Biotechnologies Corp (ADPT) reported insider transactions by CEO and Chairman Chad M. Robins involving an exercise-and-sell pattern over two days. On August 17 and 18, 2026, Robins exercised stock options for a total of 600,000 shares of common stock at an exercise price of $6.55 per share. He then sold 600,000 shares of common stock in multiple open-market transactions at weighted average prices around $24–$26 per share, as described in the price-range footnotes. The options exercised were fully vested and would have expired on February 7, 2028.
Adaptive Biotechnologies Corp (ADPT) director Peter M. Neupert reported an option exercise and significant share sales. He exercised 15,000 stock options for Common Stock at an exercise price of $6.32 per share, fully exhausting that option grant. On the same date, he sold an aggregate 124,690 shares of Common Stock in open-market transactions at weighted average prices around $25.10–$25.27 per share, as detailed in price-range footnotes.
Adaptive Biotechnologies Corporation (symbol ADPT) reports that former officer Harlan Robins plans to sell up to 215,632 shares of common stock under Rule 144 through Goldman Sachs & Co. LLC. The filing lists an aggregate market value for these planned sales of $5,496,459.68 and states that there were 159,595,842 shares of common stock outstanding. The securities to be sold were acquired on 03/04/2022 as compensation via stock options, with the planned disposition described as a compensation-related cashless exercise and same-day sale. The notice also details multiple prior sales of ADPT common stock by Robins over the past three months, each with specific share amounts, dates, and dollar values.
Adaptive Biotechnologies Corporation (ADPT) director Robert M. Hershberg filed a notice of proposed resale under Rule 144. The filing covers up to 30,664 shares of common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $748,303.36. The calculation references 159,595,842 shares outstanding as of August 18, 2026, and includes shares from stock option exercises and restricted stock.
Adaptive Biotechnologies Corp (ADPT) insider Chad Robins has filed a notice of proposed sale of common stock under Rule 144. He plans to sell 278,676 shares through Goldman Sachs & Co. LLC via a cashless exercise/same-day sale of stock options originally granted on February 7, 2018. The planned sale represents part of an issuer share base of 159,595,842 shares outstanding. Over the prior three months, Robins has already sold 321,324 shares of common stock.